Scotland says yes to BI/Lilly's Tradjenta and Lilly's Bydureon
This article was originally published in Scrip
Scotland's health technology appraisal body, the Scottish Medicines Consortium (SMC) has said a partial yes to two anti-diabetics drugs, Boehringer Ingelheim/Lilly's DPP-4 inhibitor Tradjenta (linagliptin) and Lilly's GLP1-agonist Bydureon (prolonged-release exenatide). Meanwhile it has given Roche's anticancer Tarceva (erlotinob) a full green light for some lung cancer patients.
You may also be interested in...
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.